What is the Effectiveness of Current COVID-19 Vaccines Against SARS-CoV-2 Variants? What to Know About the Need for Third Doses


RUDVAN AL L. İ. , SÖNMEZER M. Ç. , ÜNAL S.

FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, vol.26, no.3, pp.361-368, 2021 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Review
  • Volume: 26 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.5578/flora.20219703
  • Journal Name: FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI
  • Journal Indexes: Emerging Sources Citation Index, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.361-368
  • Keywords: SARS-CoV-2, COVID-19, Vaccine, Variant, P.1

Abstract

SARS-CoV-2 genetic variants from alpha (first detected in the UK) to delta (discovered in India this spring) to lambda (currently Argenti- na, Brazil, Chile, Colombia, Ecuador, and Peru) have been emerging and circulating the world. Also, these variants have raised concerns about the continued effectiveness of COVID-19 vaccines. In this review, influential variants cause countries to review their vaccine strat- egies, create new vaccine programs, and accelerate existing vaccine studies. The effectiveness of currently available COVID-19 vaccines on variants is discussed. It is also intended to shed light on what should be known about the necessity of third doses.